RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Bernard Arulanandam to Interferon-gamma

This is a "connection" page, showing publications Bernard Arulanandam has written about Interferon-gamma.
Connection Strength

3.979
  1. Nallaparaju KC, Yu JJ, Rodriguez SA, Zogaj X, Manam S, Guentzel MN, Seshu J, Murthy AK, Chambers JP, Klose KE, Arulanandam BP. Evasion of IFN-? signaling by Francisella novicida is dependent upon Francisella outer membrane protein C. PLoS One. 2011 Mar 31; 6(3):e18201.
    View in: PubMed
    Score: 0.354
  2. Jupelli M, Selby DM, Guentzel MN, Chambers JP, Forsthuber TG, Zhong G, Murthy AK, Arulanandam BP. The contribution of interleukin-12/interferon-gamma axis in protection against neonatal pulmonary Chlamydia muridarum challenge. J Interferon Cytokine Res. 2010 Jun; 30(6):407-15.
    View in: PubMed
    Score: 0.334
  3. Powell HJ, Cong Y, Yu JJ, Guentzel MN, Berton MT, Klose KE, Murthy AK, Arulanandam BP. CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection. Immunol Cell Biol. 2008 Aug-Sep; 86(6):515-22.
    View in: PubMed
    Score: 0.289
  4. Jupelli M, Guentzel MN, Meier PA, Zhong G, Murthy AK, Arulanandam BP. Endogenous IFN-gamma production is induced and required for protective immunity against pulmonary chlamydial infection in neonatal mice. J Immunol. 2008 Mar 15; 180(6):4148-55.
    View in: PubMed
    Score: 0.287
  5. Li W, Murthy AK, Guentzel MN, Seshu J, Forsthuber TG, Zhong G, Arulanandam BP. Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J Immunol. 2008 Mar 01; 180(5):3375-82.
    View in: PubMed
    Score: 0.286
  6. Murthy AK, Chambers JP, Meier PA, Zhong G, Arulanandam BP. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun. 2007 Feb; 75(2):666-76.
    View in: PubMed
    Score: 0.262
  7. Pammit MA, Raulie EK, Lauriano CM, Klose KE, Arulanandam BP. Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect Immun. 2006 Apr; 74(4):2063-71.
    View in: PubMed
    Score: 0.251
  8. Keck J, Chambers JP, Kancharla A, Bashir DH, Henley L, Schenkel K, Castillo K, Neal Guentzel M, Gupta R, Arulanandam BP. The Role of MicroRNA-155 in Chlamydia muridarum Infected lungs. Microbes Infect. 2020 09; 22(8):360-365.
    View in: PubMed
    Score: 0.164
  9. Lin H, He C, Koprivsek JJ, Chen J, Zhou Z, Arulanandam B, Xu Z, Tang L, Zhong G. Antigen-Specific CD4+ T Cell-Derived Gamma Interferon Is Both Necessary and Sufficient for Clearing Chlamydia from the Small Intestine but Not the Large Intestine. Infect Immun. 2019 06; 87(6).
    View in: PubMed
    Score: 0.156
  10. Wali S, Gupta R, Yu JJ, Lanka GKK, Chambers JP, Guentzel MN, Zhong G, Murthy AK, Arulanandam BP. Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs. Immunol Cell Biol. 2017 05; 95(5):454-460.
    View in: PubMed
    Score: 0.132
  11. Gupta R, Arkatkar T, Keck J, Koundinya GK, Castillo K, Hobel S, Chambers JP, Yu JJ, Guentzel MN, Aigner A, Christenson LK, Arulanandam BP. Antigen specific immune response in Chlamydia muridarum genital infection is dependent on murine microRNAs-155 and -182. Oncotarget. 2016 10 04; 7(40):64726-64742.
    View in: PubMed
    Score: 0.130
  12. Cunningham AL, Guentzel MN, Yu JJ, Hung CY, Forsthuber TG, Navara CS, Yagita H, Williams IR, Klose KE, Eaves-Pyles TD, Arulanandam BP. M-Cells Contribute to the Entry of an Oral Vaccine but Are Not Essential for the Subsequent Induction of Protective Immunity against Francisella tularensis. PLoS One. 2016; 11(4):e0153402.
    View in: PubMed
    Score: 0.126
  13. Lanka GK, Yu JJ, Gong S, Gupta R, Mustafa SB, Murthy AK, Zhong G, Chambers JP, Guentzel MN, Arulanandam BP. IgA modulates respiratory dysfunction as a sequela to pulmonary chlamydial infection as neonates. Pathog Dis. 2016 Apr; 74(3).
    View in: PubMed
    Score: 0.123
  14. Li W, Murthy AK, Lanka GK, Chetty SL, Yu JJ, Chambers JP, Zhong G, Forsthuber TG, Guentzel MN, Arulanandam BP. A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice. Vaccine. 2013 Nov 19; 31(48):5722-8.
    View in: PubMed
    Score: 0.105
  15. Signarovitz AL, Ray HJ, Yu JJ, Guentzel MN, Chambers JP, Klose KE, Arulanandam BP. Mucosal immunization with live attenuated Francisella novicida U112?iglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat model. PLoS One. 2012; 7(10):e47639.
    View in: PubMed
    Score: 0.099
  16. Chu P, Rodriguez AR, Arulanandam BP, Klose KE. Tryptophan prototrophy contributes to Francisella tularensis evasion of gamma interferon-mediated host defense. Infect Immun. 2011 Jun; 79(6):2356-61.
    View in: PubMed
    Score: 0.089
  17. Chaganty BK, Murthy AK, Evani SJ, Li W, Guentzel MN, Chambers JP, Zhong G, Arulanandam BP. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine. 2010 Mar 08; 28(11):2323-9.
    View in: PubMed
    Score: 0.081
  18. Yu JJ, Goluguri T, Guentzel MN, Chambers JP, Murthy AK, Klose KE, Forsthuber TG, Arulanandam BP. Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice. Clin Vaccine Immunol. 2010 Feb; 17(2):215-22.
    View in: PubMed
    Score: 0.081
  19. Cong Y, Yu JJ, Guentzel MN, Berton MT, Seshu J, Klose KE, Arulanandam BP. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine. 2009 Sep 18; 27(41):5554-61.
    View in: PubMed
    Score: 0.079
  20. Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol. 2009 Apr; 16(4):444-52.
    View in: PubMed
    Score: 0.076
  21. Cong Y, Jupelli M, Guentzel MN, Zhong G, Murthy AK, Arulanandam BP. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine. 2007 May 10; 25(19):3773-80.
    View in: PubMed
    Score: 0.067
  22. Murthy AK, Cong Y, Murphey C, Guentzel MN, Forsthuber TG, Zhong G, Arulanandam BP. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect Immun. 2006 Dec; 74(12):6722-9.
    View in: PubMed
    Score: 0.065
  23. Pammit MA, Budhavarapu VN, Raulie EK, Klose KE, Teale JM, Arulanandam BP. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother. 2004 Dec; 48(12):4513-9.
    View in: PubMed
    Score: 0.057
  24. Murthy AK, Sharma J, Coalson JJ, Zhong G, Arulanandam BP. Chlamydia trachomatis pulmonary infection induces greater inflammatory pathology in immunoglobulin A deficient mice. Cell Immunol. 2004 Jul; 230(1):56-64.
    View in: PubMed
    Score: 0.055
  25. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun. 2001 Nov; 69(11):6718-24.
    View in: PubMed
    Score: 0.046
  26. He Y, Xu H, Song C, Koprivsek JJ, Arulanandam B, Yang H, Tao L, Zhong G. Adoptive Transfer of Group 3-Like Innate Lymphoid Cells Restores Mouse Colon Resistance to Colonization of a Gamma Interferon-Susceptible Chlamydia muridarum Mutant. Infect Immun. 2021 01 19; 89(2).
    View in: PubMed
    Score: 0.044
  27. Arulanandam BP, O'Toole M, Metzger DW. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis. 1999 Oct; 180(4):940-9.
    View in: PubMed
    Score: 0.040
  28. Tang L, Yang Z, Zhang H, Zhou Z, Arulanandam B, Baseman J, Zhong G. Induction of protective immunity against Chlamydia muridarum intracervical infection in DBA/1j mice. Vaccine. 2014 Mar 10; 32(12):1407-13.
    View in: PubMed
    Score: 0.026
  29. Manam S, Chaganty BK, Evani SJ, Zafiratos MT, Ramasubramanian AK, Arulanandam BP, Murthy AK. Intranasal vaccination with Chlamydia pneumoniae induces cross-species immunity against genital Chlamydia muridarum challenge in mice. PLoS One. 2013; 8(5):e64917.
    View in: PubMed
    Score: 0.026
  30. Rodriguez AR, Arulanandam BP, Hodara VL, McClure HM, Cobb EK, Salas MT, White R, Murthy KK. Influence of interleukin-15 on CD8+ natural killer cells in human immunodeficiency virus type 1-infected chimpanzees. J Gen Virol. 2007 Feb; 88(Pt 2):641-651.
    View in: PubMed
    Score: 0.017
  31. Huber VC, Arulanandam BP, Arnaboldi PM, Elmore MK, Sheehan CE, Kallakury BV, Metzger DW. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol. 2003 Jun; 3(6):801-9.
    View in: PubMed
    Score: 0.013
  32. Buchanan RM, Briles DE, Arulanandam BP, Westerink MA, Raeder RH, Metzger DW. IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine. 2001 Feb 28; 19(15-16):2020-8.
    View in: PubMed
    Score: 0.011
  33. Buchanan RM, Arulanandam BP, Metzger DW. IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells. J Immunol. 1998 Nov 15; 161(10):5525-33.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support